ClinicalTrials.gg
CompletedNCT02288338Updated Mar 10, 2015

CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers

A Phase 1 interventional study of 1 (Lipitor®) and 1 (Ezetrol®) in Healthy, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-10.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
All
01

Study summary

A randomized open-label, multiple dose, three-treatment, three-period, six-sequence, crossover study to investigate the pharmacokinetic drug interaction between Atorvastatin and Ezetimibe after oral administration in healthy volunteers

Read the detailed description

Outcome Measures

  1. Primary endpoint AUCτ,ss, Cmax,ss of atorvastatin and free ezetimibe
  2. Second endpoint 1) AUCinf,ss, Cavg,ss, %fluctuation, tmax,ss, t1/2, CL/Fss, Vd/Fss of atorvastatin and free ezetimibe 2) AUCτ,ss, AUCinf,ss, Cmax,ss, tmax,ss, t1/2, metabolic ratio of 2-hydroxy atorvastatin and free ezetimibe
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age Eligible for Study : 19 Years to 45 Years
  2. If males, Body weight ≥ 55kg, If females, Body weight ≥ 50kg
  3. BSA ≥ 18.5, \<25
  4. Accepts healthy volunteers
  5. If female, Negative for pregnancy test at the screening and pre dose of Day 1
  6. The subjects who agree with performing during the study
  7. The subjects who agreed with written

Exclusion criteria

Exclusion Criteria:

  1. The subjects with impaired hepatic function, renal function, nervous system etc.
  2. The subjects have a gastrointestinal disease or surgery which can be effected in absorption of product
  3. The subjects with high blood pressure or low blood pressure (Systolic blood pressure>150mmHg or \<90mmHg, Diastolic blood pressure>100mmHg or \<50mmHg
  4. The subjects with abnormal Laboratory test (, ALT>1.25 fold of upper normal limit, Total >1.5 fold of upper normal limit, CPK>2 fold of upper normal limit, Estimated \<60mL/min/1.73m2 by Modification of Diet in Renal disease formula
  5. The subjects have drug abuse history within 1year or Positive for urine drug test at screening
  6. The subjects who took prescription only medicine whch can be effected in metabolism of Investigational product within 14days
  7. The subjects who took over the counter drug whch can be effected in metabolism of Investigational product within 7days
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    1(Lipitor®>Ezetrol®>Lipitor®, Ezetrol®)

    Three treatment 1. atorvastatin calcium 40mg will be administration to healthy volunteers during 7days 2. after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days 3. after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days

    Drug: 1 (Lipitor®) · Drug: 1 (Ezetrol®) · Drug: 1 (Lipitor®, Ezetrol®)

  • Experimental
    2(Ezetrol®>Lipitor®, Ezetrol®>Lipitor®)

    Three treatment 1. ezetimibe 10mg will be administered to healthy volunteers during 7days 2. after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days 3. after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days

    Drug: 2 (Ezetrol®) · Drug: 2(Lipitor®, Ezetrol®) · Drug: 2 (Lipitor®)

  • Experimental
    3(Lipitor®, Ezetrol®>Lipitor®>Ezetrol®)

    Three treatment 1. atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days 2. after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days 3. after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days

    Drug: 3(Lipitor®, Ezetrol®) · Drug: 3 (Lipitor®) · Drug: 3 (Ezetrol®)

  • Experimental
    4(Lipitor®>Lipitor®, Ezetrol®>Ezetrol®)

    1. atorvastatin calcium 40mg will be administered to healthy volunteers during 7days 2. after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days 3. after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days

    Drug: 4 (Lipitor®) · Drug: 4(Lipitor®, Ezetrol®) · Drug: 4 (Ezetrol®)

  • Experimental
    5(Ezetrol®>Lipitor®>Lipitor®, Ezetrol®)

    1. ezetimibe 10mg will be administered to healthy volunteers during 7days 2. after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days 3. after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days

    Drug: 5 (Ezetrol®) · Drug: 5 (Lipitor®) · Drug: 5 (Lipitor®, Ezetrol®)

  • Experimental
    6(Lipitor®, Ezetrol®>Ezetrol®>Lipitor®)

    1. atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days 2. after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days 3. after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days

    Drug: 6(Lipitor®, Ezetrol®) · Drug: 6 (Ezetrol®) · Drug: 6 (Lipitor®)

Interventions

  • atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg

  • After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Ezetrol® 10mg

  • Drug1 (Lipitor®, Ezetrol®)

    After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg, Ezetrol® 10mg

  • ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Ezetrol® 10mg

  • Drug2(Lipitor®, Ezetrol®)

    After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg, Ezetrol® 10mg

  • After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg

  • Drug3(Lipitor®, Ezetrol®)

    atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg, Ezetrol® 10mg

  • After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg

  • After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Ezetrol® 10mg

  • atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg

  • Drug4(Lipitor®, Ezetrol®)

    After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg, Ezetrol® 10mg

  • After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Ezetrol® 10mg

  • ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Ezetrol® 10mg

  • After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg

  • Drug5 (Lipitor®, Ezetrol®)

    After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg, Ezetrol® 10mg

  • Drug6(Lipitor®, Ezetrol®)

    atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg, Ezetrol® 10mg

  • After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days

    Also known as: Ezetrol® 10mg

  • After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days

    Also known as: Lipitor® 40mg

06

What researchers measure

Primary outcomes

  1. AUCτ,ss of atorvastatin and free ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  2. Cmax,ss of atorvastatin and free ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

Secondary outcomes

  1. AUCinf,ss of atorvastatin and free ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  2. Cavg,ss of atorvastatin and free ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  3. %fluctuation of atorvastatin and free ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  4. tmax,ss of atorvastatin and free ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  5. t1/2 of atorvastatin and free ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  6. CL/Fss of atorvastatin and free ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  7. Vd/Fss of atorvastatin and free ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  8. AUCτ,ss of 2-hydroxy atorvastatin and total ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  9. AUCinf,ss of 2-hydroxy atorvastatin and total ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  10. Cmax,ss of 2-hydroxy atorvastatin and total ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  11. tmax,ss of 2-hydroxy atorvastatin and total ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  12. t1/2 of 2-hydroxy atorvastatin and total ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

  13. metabolic ratio of 2-hydroxy atorvastatin and total ezetimibe

    Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h

    Time frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)

07

Study locations

1 site
  • ChongKunDang
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2014
First posted
Nov 11, 2014
Start
Nov 2014
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Mar 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02288338
Responsible party
Sponsor
First posted
Nov 11, 2014
Start date
Nov 2014
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Mar 10, 2015

Study contacts

Min Soo Park, Ph.D. M.D
principal investigator · Severance Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Ezetimibe

Start the discussion